# Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

> **NCT06953882** · PHASE2 · RECRUITING · sponsor: **Yale University** · enrollment: 140 (estimated)

## Conditions studied

- HER2 Negative Breast Cancer

## Interventions

- **DRUG:** Ribociclib 400mg
- **DRUG:** Letrozole 2.5mg
- **DRUG:** Anastrazole 1mg
- **DRUG:** Goserelin 3.6 MG
- **RADIATION:** Adjuvant chemotherapy

## Key facts

- **NCT ID:** NCT06953882
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-09
- **Primary completion:** 2030-09
- **Final completion:** 2030-09
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2025-07-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06953882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06953882, "Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06953882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*